Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel treatments for metabolic dysfunction‑associated steatohepatitis (MASH), formerly known as NASH.
It is the developer of the first FDA‑approved therapy for adults with moderate to advanced liver fibrosis.
Address: 200 Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428
Phone: (267) 327‑4445
-
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal
Madrigal Pharmaceuticals is making another major move in the rapidly growing liver disease treatment market, writes John George for The Philadelphia Business Journal. The West…
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
